Lyell Immunopharma Inc (LYEL)
2.68
+0.18
(+7.20%)
USD |
NASDAQ |
May 09, 16:00
2.68
0.00 (0.00%)
After-Hours: 16:43
Lyell Immunopharma Profit Margin (Quarterly): -2.02M% for March 31, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -2.02M% |
| December 31, 2023 | -407.2K% |
| September 30, 2023 | -203.4K% |
| June 30, 2023 | -236.6K% |
| March 31, 2023 | -103.0K% |
| December 31, 2022 | -17.35% |
| September 30, 2022 | -2.34M% |
| June 30, 2022 | -101.6% |
| March 31, 2022 | -12.32K% |
| Date | Value |
|---|---|
| December 31, 2021 | -2.97K% |
| September 30, 2021 | -1.77K% |
| June 30, 2021 | -2.38K% |
| March 31, 2021 | -2.25K% |
| December 31, 2020 | -1.68K% |
| September 30, 2020 | -3.34K% |
| June 30, 2020 | -3.23K% |
| March 31, 2020 | -2.33K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-2.34M%
Minimum
Sep 2022
-17.35%
Maximum
Dec 2022
-314.5K%
Average
-3.23K%
Median
Jun 2020
Profit Margin (Quarterly) Benchmarks
| GlycoMimetics Inc | -90.79K% |
| Candel Therapeutics Inc | -- |
| Eliem Therapeutics Inc | -- |
| Entrada Therapeutics Inc | 39.74% |
| NovaBay Pharmaceuticals Inc | -110.2% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -32.84% |
| Return on Assets | -28.87% |
| Return on Invested Capital | -32.84% |
| Operating Margin (Quarterly) | -1.85M% |
| Return on Net Operating Assets | -153.5% |